Literature DB >> 18437247

Synthetic methodology for the preparation of N-hydroxysulfamides.

Krishnaswamy Devanathan1, Jennifer A Bell, Patricia C Wilkins, Hollie K Jacobs, Aravamudan S Gopalan.   

Abstract

A convenient synthesis of a variety of substituted N-hydroxysulfamides from chlorosulfonyl isocyanate is reported. Alkyl groups can be introduced selectively on the N-Boc nitrogen of key intermediates 1a or 1b using the Mitsunobu reaction with alcohols. Subsequently the nitrogen carrying the silyloxy group can be alkylated under traditional conditions. Deprotection to the desired N-hydroxysulfamide can be achieved in high yields. Using this method, a number of structurally diverse N-hydroxysulfamides have been prepared. The usefulness of this methodology has further been demonstrated by the synthesis of more complex targets such as bis-hydroxysulfamide, 5, and cyclic hydroxysulfamides 7 and 8.

Entities:  

Year:  2007        PMID: 18437247      PMCID: PMC2330331          DOI: 10.1016/j.tetlet.2007.09.037

Source DB:  PubMed          Journal:  Tetrahedron Lett        ISSN: 0040-4039            Impact factor:   2.415


  21 in total

1.  Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.

Authors:  A Scozzafava; C T Supuran
Journal:  J Med Chem       Date:  2000-10-05       Impact factor: 7.446

2.  The sulfamide motif in the design of enzyme inhibitors.

Authors:  Jean-Yves Winum; Andrea Scozzafava; Jean-Louis Montero; Claudiu T Supuran
Journal:  Expert Opin Ther Pat       Date:  2006-01       Impact factor: 6.674

Review 3.  Clinical use of hydroxyurea in HIV-1 infected patients.

Authors:  I Frank
Journal:  J Biol Regul Homeost Agents       Date:  1999 Jul-Sep       Impact factor: 1.711

4.  4-Chlorobenzyl sulfonamide and sulfamide derivatives of histamine homologues: the design of potent histamine H3 receptor antagonists.

Authors:  M J Tozer; I M Buck; T Cooke; S B Kalindjian; I M McDonald; M J Pether; K I Steel
Journal:  Bioorg Med Chem Lett       Date:  1999-11-01       Impact factor: 2.823

5.  Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Authors:  S Charache; F B Barton; R D Moore; M L Terrin; M H Steinberg; G J Dover; S K Ballas; R P McMahon; O Castro; E P Orringer
Journal:  Medicine (Baltimore)       Date:  1996-11       Impact factor: 1.889

6.  Mechanistic variations in the oxidation of Piloty's acid by metal complexes.

Authors:  Patricia C Wilkins; Hollie K Jacobs; Michael D Johnson; Aravamudan S Gopalan
Journal:  Inorg Chem       Date:  2004-11-29       Impact factor: 5.165

Review 7.  The nitric oxide producing reactions of hydroxyurea.

Authors:  S Bruce King
Journal:  Curr Med Chem       Date:  2003-03       Impact factor: 4.530

8.  Carbonic anhydrase inhibitors: inhibition of isozymes I, II and IV with N-hydroxysulfonamides--a novel class of intraocular pressure lowering agents.

Authors:  F Mincione; L Menabuoni; F Briganti; G Mincione; A Scozzafava; C T Supuran
Journal:  J Enzyme Inhib       Date:  1998-07

Review 9.  Safety of hydroxyurea in the treatment of HIV infection.

Authors:  Franco Lori; Laurene M Kelly; Andrea Foli; Julianna Lisziewicz
Journal:  Expert Opin Drug Saf       Date:  2004-07       Impact factor: 4.250

Review 10.  Metal binding functions in the design of carbonic anhydrase inhibitors.

Authors:  Jean-Yves Winum; Andrea Scozzafava; Jean-Louis Montero; Claudiu T Supuran
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.